EKF Diagnostics executes share buyback on AIM

Published 09/05/2025, 13:48
EKF Diagnostics executes share buyback on AIM

LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics company, has completed a share buyback transaction, repurchasing 992,762 of its ordinary shares at a price of 21.5 pence per share. The transaction took place on Thursday, with the shares to be held in treasury.

This buyback has adjusted the total issued share capital of the company to 454,930,564 ordinary shares, each with one voting right. After accounting for the treasury shares, the total number of voting rights in the company stands at 449,460,790. These figures are relevant for shareholders who need to disclose changes in their shareholding as per the Financial Conduct Authority’s rules.

Additionally, as part of the share repurchase, EKF acquired shares from investment entities managed by Harwood. Notably, 292,762 shares were bought from Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC, with the purpose of maintaining the aggregate indirect beneficial interest of Mr. Christopher Mills, a Non-Executive Director of EKF, below the 30% threshold of total voting rights post-repurchase.

Following the transaction, Mr. Mills’ indirect interest in EKF Diagnostics totals 132,541,418 ordinary shares. The company has made it clear that this announcement contains inside information pursuant to market abuse regulations.

EKF Diagnostics operates globally, with headquarters in Penarth, near Cardiff, and manufacturing facilities in the United States and Germany. The company specializes in point-of-care analyzers in hematology and diabetes, as well as life sciences services, including the manufacturing of enzymes and custom products for diagnostic, food, and industrial applications.

This news is based on a press release statement from EKF Diagnostics Holdings plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.